NeurogesX Sinks After FDA Panel Votes Against HIV Pain Patch - BusinessWeek - NeurogesX Sinks After FDA Panel Votes Against HIV Pain PatchBusinessWeek... a specialty drugmaker that has never reported an annual profit, dropped to its all-time low trading price after the company failed to win the backing of a US advisory panel for a patch to relieve painful nerve damage commonly associated with HIV.FDA Panel: Qutenza Pain Patch for Neuropathy Not Ready for ApprovalAIDSmeds.com HIV/AIDS Treatment NewsPain Patch Rejected for HIV NeuropathyMedPage TodayFDA Panel: Pain Patch Not Yet Approvable for HIV NeuropathyFamily Practice News Digital NetworkFox News -Medscapeall 36 news articles » [Google HIV NEWS]